Financial Performance - Revenue for the year ended December 31, 2025, was RMB 1,471,013 thousand, a slight increase of 2.0% from RMB 1,442,292 thousand in the previous year[5] - Gross profit decreased to RMB 267,619 thousand, down 2.8% from RMB 275,819 thousand year-on-year[5] - Net profit for the year was RMB 139,029 thousand, significantly up from RMB 26,329 thousand in the previous year, marking a growth of 427.5%[6] - Adjusted net profit was RMB 121,152 thousand, down 14.0% from RMB 141,924 thousand in the previous year[5] - Basic earnings per share improved to RMB 1.00, compared to a loss of RMB 0.19 in the previous year[6] - Total comprehensive income for the year was RMB 178,281 thousand, compared to a loss of RMB 4,285 thousand in the previous year[7] - EBITDA for 2025 was RMB 183,632,000, compared to RMB 244,968,000 in 2024, indicating a decrease of about 25.0%[25] - Net profit for the year was approximately RMB 139.0 million, an increase of about RMB 112.7 million compared to RMB 26.3 million in the previous year, mainly due to increased convertible bond income[51] Assets and Liabilities - Non-current assets totaled RMB 1,478,095 thousand, slightly down from RMB 1,484,046 thousand in the previous year[8] - Current assets decreased to RMB 1,098,766 thousand from RMB 1,099,116 thousand year-on-year[8] - Total liabilities decreased to RMB 1,177,630 thousand from RMB 1,196,614 thousand in the previous year[9] - Total equity increased to RMB 720,828 thousand from RMB 576,623 thousand year-on-year, reflecting a growth of 25.0%[9] - The total assets as of December 31, 2025, amounted to RMB 2,576,861,000, slightly down from RMB 2,583,162,000 in 2024[25] - The company’s total liabilities decreased to RMB 1,856,033,000 in 2025 from RMB 2,006,539,000 in 2024, a reduction of approximately 7.5%[25] - As of December 31, 2025, current assets were approximately RMB 1,098.8 million, while current liabilities were approximately RMB 678.4 million, resulting in a current ratio of approximately 1.62[52] Revenue Segments - The company has three reportable segments: Comprehensive Hospital Services, Hospital Management Services, and Pharmaceutical Sales, each contributing to overall revenue[18][19][20] - Comprehensive hospital services revenue rose by about 8.2% from RMB 1,303.4 million in 2024 to RMB 1,410.7 million in 2025, primarily due to the consolidation of Cixi operations[46] - Hospital management services revenue decreased by approximately 61.7% from RMB 124.1 million in 2024 to RMB 47.5 million in 2025, mainly due to reduced services provided to managed hospitals[47] Expenses - Total costs increased by approximately 3.2% from RMB 1,166.5 million in 2024 to RMB 1,203.4 million in 2025, attributed to business consolidation[48] - Administrative expenses rose by approximately 11.2% from RMB 109.0 million in 2024 to RMB 121.2 million in 2025, also due to business consolidation[49] - Employee benefits expenses for the year ended December 31, 2025, amounted to approximately RMB 490.1 million, an increase from RMB 446.7 million in 2024[64] Accounting Policies and Compliance - The company adopted a new accounting policy, changing its functional currency from RMB to HKD effective January 1, 2025, due to operational transactions being primarily in HKD[16] - The financial statements are prepared in accordance with International Financial Reporting Standards and comply with the Hong Kong Companies Ordinance[12] - An audit committee has been established, consisting of three independent non-executive directors, to review the financial statements for the year ending December 31, 2025, ensuring compliance with applicable accounting standards and regulations[70] - The financial data in the preliminary performance announcement has been agreed upon by the auditors, KPMG, and aligns with the audited financial statements for the year[71] Corporate Governance - The company has appointed Mr. Chen as the Chairman and acting CEO following the resignation of the previous CEO and Chairman on June 23, 2020, to ensure normal operations during the transition[68] - The company confirms that all directors have complied with the standard code of conduct for securities trading for the full year ending December 31, 2025[69] Future Plans and Investments - The company plans to initiate an innovation transformation action plan in 2026, focusing on patient-centered services and technology empowerment[44] - The group aims to enhance operational efficiency through investments in information technology and supply chain management, establishing a digital transformation infrastructure[44] - As of December 31, 2025, the company has no significant investments or future plans related to major investments or capital assets[59] Dividends and Shareholder Returns - The company did not declare any dividends for the fiscal year ending December 31, 2025, consistent with the previous year[39] - The company did not recommend a final dividend for the year ended December 31, 2025[63] Debt and Financing - The maturity date of the convertible bonds issued to Yufeng, amounting to HKD 468.0 million, has been extended from September 30, 2025, to September 30, 2027[55] - The maturity date of the convertible bonds issued to Hony Fund VIII, amounting to approximately HKD 773.9 million, has also been extended from September 30, 2025, to September 30, 2027[56] - Total borrowings decreased from RMB 82.1 million in 2024 to RMB 69.0 million in 2025, with a decrease in the interest-bearing debt ratio from 3.2% to 2.7%[52] Risk Management - The company faces foreign exchange risks primarily related to USD and HKD transactions, with no hedging instruments currently in use[60] - As of December 31, 2025, the company provided guarantees for loans totaling RMB 173.0 million and RMB 104.0 million for Jinhua Guangfu Hospital[61] Securities Transactions - There were no purchases, sales, or redemptions of the company's listed securities during the review year[65]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容 而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HOSPITAL CORPORATION 弘和仁愛醫療集團有限公司 Hospital Corporation of China Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：3869） 建議修訂現有組織章程大綱及細則及 採納第三次經修訂和重述組織章程大綱及細則 本公告乃由弘和仁愛醫療集團有限公司（「本公司」）根據香港聯合交易所有限公司（「聯交 所」）證券上市規則（「上市規則」）第13.51(1)條而作出。 董事長 陳帥 香港，二零二六年三月二十六日 建議修訂及建議採納經修訂組織章程大綱及細則須待股東於本公司將召開的應屆股東週 年大會（「股東週年大會」）上以特別決議案方式考慮及批准後，方告生效。 — 1 — 一份載有（其中包括）有關建議修訂及建議採納經修訂組織章程大綱及細則的詳情，連同 股東週年大會通告的股東週年大會通函，將於適當時候刊發。 代表董事會 弘和仁 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示，概不會就因本公告全部或任何部分內 容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 HOSPITAL CORPORATION 陳帥 香港，二零二六年三月十六日 於本公告日期，本公司董事包括執行董事陳帥先生、蒲成川先生及潘建麗女士；非執行 董事劉路女士及王楠女士；及獨立非執行董事党金雪先生、史錄文先生及周向亮先生。 弘和仁愛醫療集團有限公司（「本公司」）董事會（「董事會」）謹此公佈，本公司將於二零 二六年三月二十六日（星期四）舉行董事會會議，藉以（其中包括）考慮及（如認為適當）批 准本公司及其附屬公司截至二零二五年十二月三十一日止年度之全年業績及其發佈，並 考慮派發末期股息（如有）。 承董事會命 弘和仁愛醫療集團有限公司 董事長 弘和仁愛醫療集團有限公司 Hospital Corporation of China Limited （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：3869） 董事會會議日期 ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 弘和仁愛醫療集團有限公司（於開曼群島註冊成立的有限公司) 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03869 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | 本月底法定/註冊 ...

致：香港交易及結算所有限公司 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 公司名稱: 弘和仁愛醫療集團有限公司（於開曼群島註冊成立的有限公司) 呈交日期: 2026年2月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03869 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | 本月底法定/註冊股本總額： ...

Core Viewpoint - ST Zhizhi (603869.SH) expects a net profit attributable to shareholders of 29.05 million to 39 million yuan for the year 2025, representing a year-on-year increase of 40.06% to 88.04% [1] Group 1: Performance Drivers - The anticipated profit growth is attributed to the robust performance of the company's core business, rapid breakthroughs in new business areas, and refined internal management [1] - The core business segment, Juyuan Network, continues to maintain a steady growth trend, laying a solid foundation for overall performance improvement [1] - The company has successfully identified industry development trends and actively advanced its enterprise digitalization business, contributing new profit growth points and enriching its profit structure [1] Group 2: Strategic Insights - The performance increase reflects the company's deep focus on core business, proactive expansion into new sectors, and ongoing efforts in refined management [1] - This comprehensive achievement highlights the company's clear development strategy and strong operational resilience [1]

Core Viewpoint - ST Zhizhi (603869.SH) expects a significant increase in net profit for the year 2025, indicating strong growth potential and effective cost management strategies [1] Financial Performance - The company anticipates a net profit attributable to shareholders of between 29.05 million and 39 million yuan for 2025, representing a year-on-year increase of 40.06% to 88.04% [1] - The expected net profit after deducting non-recurring gains and losses is projected to be between 13.5 million and 20 million yuan, reflecting a substantial year-on-year increase of 164.21% to 195.13% [1] Business Segments - The core business segment, Ju'an Network, continues to show steady growth, providing a solid foundation for overall performance [1] - The company's digital intelligence business is progressing well, contributing new profit growth points [1] Cost Management - The company has strengthened its control over period expenses, optimizing the sales team structure and reducing related labor costs [1] - R&D resources have been refocused on core business areas such as Ju'an Network and digital intelligence, leading to a reduction in R&D expenses [1] Financial Stability - The company has increased efforts in receivables collection and recovery, resulting in the reversal of some impairment losses, which further enhances financial stability [1]

截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 弘和仁愛醫療集團有限公司（於開曼群島註冊成立的有限公司) 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03869 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | 本月底法定/註 ...

Core Viewpoint - ST Zhizhi (603869.SH) announced that its wholly-owned subsidiary, New Intelligence Cognitive Data Service Co., Ltd., received a property tax refund for the year 2024, amounting to 3.4239 million yuan, which represents 16.51% of the company's audited net profit attributable to shareholders for the most recent fiscal year [1][1][1] Summary by Relevant Sections - Tax Reduction Approval: The company received approval from the Shanghai Pudong New Area Taxation Bureau for a 100% reduction in property tax for the period from January 1, 2024, to December 31, 2024 [1][1][1] - Refund Amount: The total property tax refund received on December 17, 2025, was 3.4239 million yuan [1][1][1] - Impact on Financials: The refund constitutes 16.51% of the company's latest audited net profit attributable to shareholders [1][1][1]

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 弘和仁愛醫療集團有限公司（於開曼群島註冊成立的有限公司) 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03869 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | 0.001 HKD | | | 500,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.001 HKD | | 500,000 | 本月底法定/ ...